Key Investor Signals
Reached 91.7% AUROC on held-out benchmark data
The development model achieved 91.7% AUROC, 82.2% sensitivity and 84.1% specificity in company-run testing using public heart-sound data.
Top 10 in Swiss >>venture>> Medtech & Healthcare
AuscultaNet was named a 2026 >>venture>> semifinalist in Switzerland's Medtech & Healthcare vertical, among 10 selected from a record 451 applications.
Joined SITEM’s MedTech development program
AuscultaNet joined the SITEM MedTech Booster in January 2026, gaining regulatory mentoring and access to a hospital-focused startup network.
Other Positive Signals
- Joined Swiss startup days’ 2026 Newcomers deep-tech cohort for early-stage Swiss ventures.
Team
Rachid Lagbila
CEO and Co-founder
- Brings 13+ years in safety-critical systems across MedTech and automotive, including verification, reliability and regulatory work.
- Led system verification at mylife Diabetescare from 2023, including reliability assessment and long-term device testing.
- Managed system integration and verification at Continental from 2019 to 2023, overseeing project testing and quality metrics.
Mohamed Aymen Lagbila
CDPO and Co-founder
- Data & AI engineer and embedded-system architect leading AI integration and device architecture at AuscultaNet.
- Works as an Azure Data Engineer focused on data platforms, DataOps and cloud architecture at Yellowsys.
- Published TuniMobile, a business app for mobile recharge-ticket generation, demonstrating end-to-end software product execution.
Product
AuscultaNet processes digital stethoscope recordings on the device. Its development system combines murmur detection, timing classification and grade estimation with a structured four-site examination and clinical recommendation.
Recording a structured heart examination
The clinician records heart sounds at the aortic, pulmonary, tricuspid and mitral listening sites. The system is designed to accept digital stethoscope recordings and combine findings from the four locations.
Analyzing heart sounds on the device
An offline AI model detects murmurs and classifies them as systolic, diastolic or continuous, describing when they occur in the heartbeat. Local processing keeps recordings on the device during analysis.
Supporting referral decisions
The interface presents findings and a prioritized clinical recommendation, including echocardiography when further investigation is needed. Structured record export is designed for health-record integration.
Market Overview
Valvular heart disease becomes more common with age and can remain undetected until complications emerge. Primary care is often the first place a murmur is heard, while echocardiography confirms the diagnosis. This creates demand for tools that help clinicians identify which patients need further cardiac evaluation.
A 2026 nationally representative US study found moderate-or-greater valve disease in 8.2% of adults aged 65–85, rising to 14.7% at ages 80–85. That translates to about 4.7 million older Americans today, with the affected population projected to reach 6.5 million by 2060 as the population ages.
Moderate or severe valve disease affected 8.2% of US adults aged 65–85 in the PREVUE-VALVE study.
Moderate or severe valve disease affected 14.7% of US adults aged 80–85 in PREVUE-VALVE.
An estimated 4.7 million US adults aged 65–85 currently have moderate or severe valvular heart disease.
US adults aged 65–85 with moderate or severe valve disease are projected to rise to 6.5 million by 2060.
Comparable Outcomes
Preventice Solutions
Developed wearable cardiac monitors and remote services that detected irregular heart rhythms outside hospitals. Boston Scientific agreed to acquire Preventice in 2021 for $925 million upfront plus up to $300 million tied to commercial milestones.
Bardy Diagnostics
Developed the CAM patch, a wearable ECG monitor that records cardiac rhythms over extended periods to help clinicians detect arrhythmias. Hillrom acquired Bardy Diagnostics in August 2021 for total consideration of $434.2 million.
Interested in More Startups Like AuscultaNet?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.